This study will evaluate the safety and efficacy of the injectable drug cabotegravir (CAB LA), for pre-exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
Location: REDI (East Bay)
Please contact Jamie Carroll-Mandelk MandelJ@sutterhealth.org about HPTN083View study details on ClinicalTrials.gov
Please note that trial statuses change frequently. For the most up-to-date information, please contact the Research Department at 510.204.4155.
November 03, 2016